Role of dynamic perfusion magnetic resonance imaging in patients with local advanced rectal cancer

Table 2 Differences in terms of perfusion parameters between responders and non-responders, in the healthy rectal wall, determines through a dynamic contrast enhanced magnetic resonance imaging study during staging (MR1) and restaging (MR2) of rectal cancer after chemo-radiotherapy

DCE-MRI parameters	Responders			Non-responders
	MR1	MR2	P value	MR1	MR2	P value
RAE (mean ± SD)	62 ± 33	51 ± 8	0.77	53 ± 50	63 ± 33	0.47
RVE (mean ± SD)	70 ± 40	60 ± 14	0.73	81 ± 46	69 ± 42	0.68
RLE (mean ± SD)	72 ± 35	76 ± 10	0.49	92 ± 42	63 ± 52	0.61
ME (mean ± SD)	662 ± 98	882 ± 251	0.11	952 ± 357	847 ± 358	0.87
TTP (mean ± SD)	230 ± 61	223 ± 32	0.64	204 ± 97	151 ± 56	0.05
AUC (mean ± SD)	120261 ± 46709	114347 ± 32930	0.74	108516 ± 45766	114187 ± 28584	0.99

DCE-MRI: Dynamic-contrast enhanced magnetic resonance imaging; RAE: Relative arterial enhancement; RVE: Relative venous enhancement; RLE: Relative late enhancement; ME: Maximum enhancement; TTP: Time to peak; AUC: Area under the curve.